Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATAPEMBRO: pembrolizumab with ataluren in metastatic colorectal or endometrial cancer
NL-OMON23548Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and ataluren in colorectal adenocarcinoma and endometrial cancer (EC) (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety and toxicity and Objective response rate. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
pembrolizumabataluren
03
Conditions
colorectal adenocarcinomaendometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON23548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23548.